Pyrazolopyrimidines as cyclin dependent kinase inhibitors

US7119200B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Pharmacopeia Drug Discovery, Inc. · US

Inventors

• Timothy J. Guzi · Chatham, US
• Kamil Paruch · Garwood, US
• Michael P. Dwyer · Scotch Plains, US
• Ronald J. Doll · Maplewood, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Alan K. Mallams · Hackettstown, US
• Carmen Alvarez · Roselle Park, US
• Kartik M. Keertikar · Plainsboro, US
• Jocelyn Rivera · Monmouth Junction, US
• Tin-Yau Chan · Edison, US
• Vincent S. Madison · Mountain Lakes, US
• Thierry O. Fischmann · Scotch Plains, US
• Lawrence Wayne Dillard · Yardley, US
• Vinh D. Tran · Willow View Lane, US
• Zhen Min He · Princeton, US
• Ray Anthony James · Bristol, US
• Haengsoon Park · Plainsboro, US
• Vidyadhar M. Hobbs · Somerville, US
• Douglas W. Hobbs · Yardley, US

Key dates

• Filing date: Feb 11, 2004
• Grant date: Oct 10, 2006
• Expiry date: Jul 25, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.